在固体和血液癌症中对转化延长抑制剂的敏感性
Nathan Gomes1,2, Barbara Frederick1,2, John Tentler3,4
1Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO, 80309-0347, USA.
Scientific reports
|July 2, 2025
概括
一种蛋白质合成抑制剂SVC112通过耗尽不稳定的癌症蛋白质,显示出作为癌症治疗的希望. 它的有效性因癌症类型而异,与特定的分子标记物相关,并诱导亡以控制瘤生长.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 蛋白质合成抑制剂通过向不稳定的coproteins,为癌症提供治疗策略.
- SVC112是一种翻译延长抑制剂,此前已经证明对头部和部状细胞癌 (HNSCC) 的干细胞和瘤异种移植的疗效.辐射后.
研究的目的:
- 评估SVC112在不同癌细胞系中的独立抗癌活性.
- 为了确定SVC112灵敏度和耐药性的分子相关物.
- 在临床前模型中确定SVC112诱导的亡对治疗结果的预测值.
主要方法:
- 在一个具有不同起源的癌症细胞系小组中选SVC112疗效.
- 对分子标记物的分析,包括亡/生存因子的基底表达和c-Myc酸化,与SVC112敏感性相关.
- 在SVC112治疗后,对老鼠异种移植模型的瘤生长控制和生存益处的评估.
主要成果:
- 在不同癌症细胞系中,SVC112的生长抑制率为1600倍,这表明敏感度可变.
- 血液癌症的敏感性与亡/生存因子的基底表达相关.
- 结直肠癌的敏感性与c-Myc酸化相关.
- 在体内,SVC112诱导的亡预测了瘤生长控制和生存益处.
结论:
- SVC112表现出独立的抗癌活性,其灵敏度受癌症特异性分子形状的影响.
- 翻译抑制剂的效用可能取决于固有的癌细胞依赖性和影响瘤性蛋白质稳定性的翻译后修改.
- SVC112具有作为向癌症治疗的潜力,因此需要对其预测生物标志物进行进一步的研究.
相关概念视频
01:31Translation
144.3K
Lesson: Translation
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
Translation is the process of synthesizing proteins from the genetic information carried by messenger RNA (mRNA). Following transcription, it constitutes the final step in the expression of genes. This process is carried out by ribosomes, complexes of protein and specialized RNA molecules. Ribosomes, transfer RNA (tRNA), and other proteins produce a chain of amino acids—the polypeptide—as the end product of translation.
Translation Produces the Building Blocks of...
144.3K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
02:56Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
02:28Leaky Scanning
5.2K
During most eukaryotic translation processes, the small 40S ribosome subunit scans an mRNA from its 5' end until it encounters the first start AUG codon. The large 60S ribosomal subunit then joins the smaller one to initiate protein synthesis. The location of the translation initiation is largely determined by the nucleotides near the start codon as there may be multiple translation initiation sites present on the mRNA. Marilyn Kozak discovered that the sequence RCCAUGG (where R...
5.2K
02:33Initiation of Translation
34.6K
Initiating translation is complex because it involves multiple molecules. Initiator tRNA, ribosomal subunits, and eukaryotic initiation factors (eIFs) are all required to assemble on the initiation codon of mRNA. This process consists of several steps that are mediated by different eIFs.
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
First, the initiator tRNA must be selected from the pool of elongator tRNAs by eukaryotic initiation factor 2 (eIF2). The initiator tRNA (Met-tRNAi) has conserved sequence elements including modified bases at...
34.6K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K